These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 9845541)
1. Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. Daniel PT; Kroidl A; Kopp J; Sturm I; Moldenhauer G; Dörken B; Pezzutto A Blood; 1998 Dec; 92(12):4750-7. PubMed ID: 9845541 [TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Demanet C; Brissinck J; De Jonge J; Thielemans K Blood; 1996 May; 87(10):4390-8. PubMed ID: 8639800 [TBL] [Abstract][Full Text] [Related]
3. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses. Manzke O; Tesch H; Lorenzen J; Diehl V; Bohlen H Int J Cancer; 2001 Feb; 91(4):516-22. PubMed ID: 11251975 [TBL] [Abstract][Full Text] [Related]
4. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma. Demanet C; Brissinck J; De Jonge J; Thielemans K J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370 [TBL] [Abstract][Full Text] [Related]
5. CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma. Manzke O; Titzer S; Tesch H; Diehl V; Bohlen H Cancer Immunol Immunother; 1997; 45(3-4):198-202. PubMed ID: 9435873 [TBL] [Abstract][Full Text] [Related]
6. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cochlovius B; Kipriyanov SM; Stassar MJ; Schuhmacher J; Benner A; Moldenhauer G; Little M Cancer Res; 2000 Aug; 60(16):4336-41. PubMed ID: 10969772 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model. Panjideh H; Müller G; Koch M; Wilde F; Scheu S; Moldenhauer G; Lipp M Int J Cancer; 2014 Dec; 135(11):2623-32. PubMed ID: 24729415 [TBL] [Abstract][Full Text] [Related]
8. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease. da Costa L; Renner C; Hartmann F; Pfreundschuh M Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145 [TBL] [Abstract][Full Text] [Related]
9. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody. Csóka M; Strauss G; Debatin KM; Moldenhauer G Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680 [TBL] [Abstract][Full Text] [Related]
10. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity. Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659 [TBL] [Abstract][Full Text] [Related]
11. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation. Manzke O; Tesch H; Borchmann P; Wolf J; Lackner K; Gossmann A; Diehl V; Bohlen H Int J Cancer; 2001 Feb; 91(4):508-15. PubMed ID: 11251974 [TBL] [Abstract][Full Text] [Related]
12. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells. Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H Cancer Res; 1997 May; 57(9):1704-9. PubMed ID: 9135012 [TBL] [Abstract][Full Text] [Related]
13. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079 [TBL] [Abstract][Full Text] [Related]
14. T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand. Wooldridge JE; Dahle CE; Weiner GJ Cancer Immunol Immunother; 1997; 45(3-4):174-9. PubMed ID: 9435867 [TBL] [Abstract][Full Text] [Related]
15. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099 [TBL] [Abstract][Full Text] [Related]
16. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells. Cochlovius B; Kipriyanov SM; Stassar MJ; Christ O; Schuhmacher J; Strauss G; Moldenhauer G; Little M J Immunol; 2000 Jul; 165(2):888-95. PubMed ID: 10878363 [TBL] [Abstract][Full Text] [Related]
17. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16. Pörtner LM; Schönberg K; Hejazi M; Brünnert D; Neumann F; Galonska L; Reusch U; Little M; Haas R; Uhrberg M Cancer Immunol Immunother; 2012 Oct; 61(10):1869-75. PubMed ID: 22976535 [TBL] [Abstract][Full Text] [Related]
18. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody. Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739 [TBL] [Abstract][Full Text] [Related]
19. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880 [TBL] [Abstract][Full Text] [Related]
20. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]